[Cancer Management and Research] A review of fertility complications induced by chemotherapy and radiotherapy, as well as possible treatment options for HL patients with fertility problems.
A review of SEER data revealed trends in incidence of advanced Hodgkin lymphoma, discrepancies among subgroups, and survival over 3 decades.
Researchers conducted a retrospective study to assess 18F-FDG PET/CT vs bone marrow biopsy to detect bone marrow involvement among pediatric patients with Hodgkin lymphoma.
This marks the fifth FDA-approved indication for brentuximab vedotin and the first approval for front-line stage III or IV CHL in more than 4 decades.
A review of management approaches to Hodgkin lymphoma in Europe vs the United States/North America demonstrates that although some differences exist, worldwide studies that would enhance patient outcomes are feasible.
Patients treated with BEACOPP have improved outcomes compared with ABVD but also face significant adverse events. A major goal of therapy is therefore to minimize toxicity.
Patients who received the recommended phase 1 dose of brentuximab vedotin and bendamustine had an overall response of 78%.
Researchers randomly assigned 1334 patients with untreated stage III or IV HL to receive A + AVD or ABVD for 6 cycles.
Among the 60 evaluable patients, the objective response rate was 83%, with CR rate of 62%.
The purpose of this study was to assess the benefit of brentuximab vedotin, an effective and well-tolerated agent for relapsed cHL, when added to standard eBEACOPP.
